ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Chickenpox Vaccine

Also written as “Varicella Vaccine”, “Investigational live attenuated varicella vaccine” and “Zoster Vaccine, Live”.

Its studies are mostly in Chickenpox · Herpes Zoster · Meningococcal Infections · Measles · Streptococcal Infections, led by 6 companies.

Drug pageChickenpox Vaccine: every studyMany companies study it; this page follows only the 43 they lead. All 76 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 7, 200743 company-led studies, 6 open or runningNext primary completion: Dec 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck210 open or runningphase 4since Feb 7, 2007Apr 22, 2005none ahead
Sinovac Biotechits history only124 open or runningphase 4since Oct 14, 2021Nov 14, 2016Dec 2028phase 4 · NCT06484686
GlaxoSmithKlineits history only60 open or runningphase 3since Sep 13, 2005Sep 13, 2005none ahead
Sinopharmits history only22 open or runningphase 3since Dec 20, 2022Dec 20, 2022none ahead
Changchun Changsheng Life Science and Technologyits history only10 open or runningphase 4since Oct 24, 2013Oct 24, 2013none ahead
GC Biopharmaits history only10 open or runningphase 3since Nov 28, 2017Nov 28, 2017none ahead

Also a collaborator on its studies: Beijing Institute of Biological Products.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Apr 22, 2005.

  1. Sep 21, 2007Phase 3 study in Herpes ZosterNCT00534248 · 22,439 enrolled
  2. Oct 17, 2007Phase 2 study in Herpes ZosterNCT00546819 · 309 enrolled
  3. Oct 29, 2007Phase 4 study in Herpes ZosterNCT00550745 · 11,999 enrolled
  4. Nov 19, 2007Phase 3 study in Prevention of : Herpes-ZosterNCT00561080 · 759 enrolled
  5. May 16, 2008Phase 4 study in Herpes ZosterNCT00681031 · 96 enrolled
  6. Jan 9, 2009Phase 3 study in ChickenpoxNCT00822237 · 598 enrolled
  7. Nov 19, 2010Phase 3 study in Herpes ZosterNCT01245751 · 600 enrolled
  8. Jun 28, 2011Phase 1 study in Herpes ZosterNCT01385566 · 223 enrolled
  9. Jul 7, 2011Phase 3 study in Herpes ZosterNCT01391546 · 354 enrolled
  10. Jan 4, 2012Phase 3 study in Herpes ZosterNCT01505647 · 498 enrolled
  11. Feb 2, 2012Phase 3 study in Herpes ZosterNCT01527370 · 250 enrolled
  12. Feb 17, 2012Phase 4 study in Herpes ZosterNCT01556451 · 180 enrolled
  13. Aug 7, 2015Phase 3 study in Herpes ZosterNCT02519855 · 882 enrolled
  14. Feb 14, 2019Phase 3 study in ChickenpoxNCT03843632 · 150 enrolled · Russian Federation

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 21 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03843632Chickenpox · Russian Federation3CompletedJun 19, 2020150
NCT02519855Herpes Zoster3CompletedJan 26, 2016882
NCT01556451Herpes Zoster4CompletedOct 2012180
NCT01527370Herpes Zoster3CompletedApr 9, 2013250
NCT01505647Herpes Zoster3CompletedJul 2012498
NCT01391546Herpes Zoster3CompletedOct 15, 2012354
NCT01385566Herpes Zoster1CompletedMay 2013223
NCT01245751Herpes Zoster3CompletedJul 2012600
NCT00822237Chickenpox3CompletedOct 2009598
NCT00681031Herpes Zoster4CompletedJun 25, 200896
NCT00561080Prevention of : Herpes-Zoster3CompletedJun 3, 2009759
NCT00550745Herpes Zoster4CompletedJan 200911,999
NCT00546819Herpes Zoster2CompletedAug 2010309
NCT00534248Herpes Zoster3CompletedJan 201022,439
NCT00496327Chickenpox3CompletedOct 6, 2005100
NCT00444860Varicella Virus Infection3CompletedMay 2007150
NCT00432731Chickenpox · France, Italy4CompletedSep 2005500
NCT00432523Measles · France, Germany3CompletedSep 5, 2005752
NCT00322231Herpes Zoster3CompletedJul 2007101
NCT00231816Herpes Zoster3CompletedMar 2006763
NCT00109122Herpes Zoster2CompletedFeb 2003180

How it is read

Names in the registry

  • “Varicella Vaccine”, 4 entries
  • “Investigational live attenuated varicella vaccine”, 4 entries
  • “Zoster Vaccine, Live”, 3 entries
  • “Varicella Virus Vaccine Live”, 2 entries
  • “Live Attenuated Varicella Vaccine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.